InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
2
T+90 hit rate
0%
T+90 mean return
-32.0%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Shearman Mark S, Vice-Président Exécutif. Director active across 1 company, notably Editas Medicine, Inc.. Aggregated, 8 reports have been logged. Split: 0 buy · 2 sells. Total volume traded: €75k. Activity tracked since 14 June 2021. The latest transaction was filed on 13 February 2023 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Declarations8 total
2,790 shares@ US$9.665333.8% of flowCommon StockSEC:0001415889-23-002604:0
5,145 shares@ US$10.05730.025% mcap100.0% of flowCommon StockSEC:0001415889-22-006631:0
31,709 shares0Common StockSEC:0001415889-22-001224:0
31,709 shares0Common StockSEC:0001415889-22-001224
9,084 shares0Common StockSEC:0001179110-21-011225
9,084 shares0Common StockSEC:0001179110-21-011225:0
32,701 shares0Common StockSEC:0001179110-21-006778
32,701 shares0Common StockSEC:0001179110-21-006778:0
8 of 8 declarations
About Shearman Mark S
Mark S. Shearman is the Executive Vice President and Chief Scientific Officer at Editas Medicine, Inc. He oversees the company's research and development activities, focusing on innovation and scientific advancement. With a strong background in the biopharmaceutical sector, he plays a key role in developing new therapies. His expertise is essential in guiding research and development initiatives.
